Traws Pharma, Inc. Restricted Cash and Cash Equivalents, Noncurrent
Traws Pharma, Inc. (TRAW) had Restricted Cash and Cash Equivalents, Noncurrent of $125.00 thousand as of 2014-09-30, per its 10-Q filed 2014-11-14.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2015-03-30
- 2014-09-30: Restricted Cash and Cash Equivalents, Noncurrent $125.00K.
- 2014-06-30: Restricted Cash and Cash Equivalents, Noncurrent $125.00K.
- 2014-03-31: Restricted Cash and Cash Equivalents, Noncurrent $125.00K.
- 2013-12-31: Restricted Cash and Cash Equivalents, Noncurrent $125.00K.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2014-09-30 | $125.00K 10-Q · filed 2014-11-14 |
| 2014-06-30 | $125.00K 10-Q · filed 2014-08-14 |
| 2014-03-31 | $125.00K 10-Q · filed 2014-05-15 |
| 2013-12-31 | $125.00K 10-K · filed 2015-03-30 |
| 2013-09-30 | $125.00K 10-Q · filed 2013-11-14 |
| 2013-06-30 | $125.00K 10-Q · filed 2013-09-06 |
| 2012-12-31 | $125.00K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |